Author

G. Inghirami

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Approach:statistical model· 2

Frequent Co-Authors

A. Chang· 1 shared A. Dhogan· 1 shared A. Melnick· 1 shared A. Mottok· 1 shared A. Younes· 1 shared B. Callaghan· 1 shared C. A. Troxell· 1 shared C. C. Au· 1 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Chang

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Mutability and hypermutation antagonize immunoglobulin codon optimality

J. J. McGrath, J. Park, C. A. Troxell, J. C. Chervin, L. Li, J. R. Kent, S. Changrob, Y. Fu, M. Huang, N.-Y. Zheng, G. D. Wilbanks, S. A. Nelson, J. Sun, G. Inghirami, M. L. L. Madariaga, , P. C. Wilson

The paper examines how immunoglobulin codon optimality interacts with mutability and hypermutation in antibody evolution, finding that codon deoptimization correlates with expression loss and is constrained by selective pressures.

bioRxiv · Mar 13, 2024Immunology

HSP90 facilitates oncogenic alterations of metabolism in B-cell lymphomas

M. N. Calvo-Vidal, N. Zamponi, J. Krumsiek, M. A. Stockslager, M. V. Revuelta, J. M. Phillip, R. Marullo, N. Kotlov, J. Patel, S. N. Yang, L. Yang, T. Taldone, C. Thieblemont, J. P. Leonard, P. Martin, , L. Cerchietti

This study shows HSP90 supports metabolic compartmentalization in B-cell lymphomas, and its inhibition reduces cancer metabolism.

bioRxiv · May 29, 2020 · PreprintCancer Biology

Unacylated ghrelin and AZP531 suppress the 3D growth of breast cancers

C. C. Au, J. B. Furness, K. Britt, S. Oshchepkova, H. Ladumor, K. Y. Soo, B. Callaghan, C. Gerard, G. Inghirami, V. Mittal, Y. Wang, X.-Y. Huang, J. A. Spector, E. Andreopoulou, P. Zumbo, , K. A. Brown

This study shows unacylated ghrelin and its analog AZP531 inhibit breast cancer growth in 3D cultures and xenografts by suppressing MAPK signaling and inducing apoptosis.

bioRxiv · Jan 22, 2020 · PreprintCancer Biology

Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma

P. Mondello, S. Tadros, M. Teater, L. Fontan, A. Chang, N. Jain, S. Singh, M. C. J. Ma, H. Yang, E. Toska, S. Alig, M. Durant, E. de Stanchina, A. Mottok, L. Nastoupil, , M. Green

This paper shows that HDAC3 inhibitors reverse CREBBP mutation-driven epigenetic changes in lymphoma, inhibiting tumor growth and restoring immune surveillance.

bioRxiv · Jan 27, 2019Cancer Biology